IMMUNE REACTIVE PROTEINS IN RENAL-CELL CARCINOMA PATIENTS TREATED BY IFN-ALPHA ALONE OR IN COMBINATION WITH VINBLASTINE

被引:0
|
作者
JURANIC, Z [1 ]
STANOJEVICBAKIC, N [1 ]
MALETIC, V [1 ]
BORKOVACKI, R [1 ]
机构
[1] UNIV BELGRADE, CTR CLIN, DEPT UROL, YU-11000 BELGRADE, YUGOSLAVIA
关键词
RENAL CELL CARCINOMA; HUMORAL IMMUNITY; IFN-ALPHA;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunoreactive proteins - serum immunoglobulins and immune complexes were evaluated in renal cell carcinoma (RCC) patients. The analyses were done after radical nephrectomy before, at the end, and six months after the therapy, with IFN alpha alone (in patients in Stage II) or IFN alpha in the combination with vinblastine (in patients in Stage III and IV of the disease). Data obtained before immuno- or immunochemotherapy show significant increase in IgG and IgA concentrations in RCC patients in all stages of the disease investigated - in comparison to controls, while circulating immune complexes were significantly elevated only in patients in the advanced Stages of the disease (III and IV). The unchanged IgM level was found in all untreated RCC patients regarding the controls. Immuno- or immunochemotherapy did not affect the immunoreactive proteins (Ig and CIC) in the investigated patients, without respect to their clinical response to the applied therapy.
引用
收藏
页码:229 / 232
页数:4
相关论文
共 50 条
  • [1] Mechanisms of IFN-alpha Resistance in Renal Cell Carcinoma
    Pathe, Eric
    Tate, David J.
    Trinh, Janie
    Finkel-Jimenez, Beatriz
    Zea, Arnold H.
    JOURNAL OF IMMUNOTHERAPY, 2011, 34 (02) : 224 - 224
  • [2] Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma
    Groenewegen, G.
    Walraven, M.
    Vermaat, J.
    de Gast, B.
    Witteveen, E.
    Giles, R.
    Haanen, J.
    Voest, E.
    BRITISH JOURNAL OF CANCER, 2012, 106 (02) : 284 - 289
  • [3] Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma
    G Groenewegen
    M Walraven
    J Vermaat
    B de Gast
    E Witteveen
    R Giles
    J Haanen
    E Voest
    British Journal of Cancer, 2012, 106 : 284 - 289
  • [4] MITOGEN-INDUCED LYMPHOPROLIFERATIVE RESPONSE AND PHAGOCYTIC-ACTIVITY OF MONOCYTES IN RENAL-CELL CARCINOMA PATIENTS TREATED BY INTERFERON A ALONE OR IN COMBINATION WITH VINBLASTINE
    STANOJEVICBAKIC, N
    VUCKOVICDEKIC, L
    MALETIC, V
    BORKOVACKI, R
    ONCOLOGY REPORTS, 1995, 2 (05) : 891 - 895
  • [5] IMMUNE STUDIES IN RENAL-CELL CARCINOMA (RCC) PATIENTS TREATED WITH INTERFERON
    LESLIE, WT
    TAYLOR, SG
    HARRIS, JE
    BRAUN, DP
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 321 - 321
  • [6] A PHASE-II STUDY OF VINBLASTINE IN COMBINATION WITH ACRIVASTINE IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA
    BERLIN, J
    KING, AC
    TUTSCH, K
    FINDLAY, JW
    KOHLER, P
    COLLIER, M
    CLENDENINN, NJ
    WILDING, G
    INVESTIGATIONAL NEW DRUGS, 1994, 12 (02) : 137 - 141
  • [7] IFN-ALPHA THERAPY OF RENAL-CELL CARCINOMA - DEFECT OF LYMPHOCYTE SENSITIVITY TO MITOGENIC AND ACTIVATING CYTOKINE SIGNALS IN PATIENTS NOT-RESPONDING TO THERAPY
    INDROVA, M
    BUBENIK, J
    JAKOUBKOVA, J
    SOBOTA, V
    HELMICHOVA, E
    SIMOVA, J
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1995, 7 (03) : 523 - 526
  • [8] IFN-alpha therapy of renal cell carcinoma: Questions regarding cellular immunotherapy
    Characiejus, D
    Pasukoniene, V
    Kazlauskaite, N
    Mauricas, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 20 - 20
  • [9] EVALUATION OF THE COMBINATION OF VINBLASTINE AND QUINIDINE IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA - A PHASE-I STUDY
    AGARWALA, SS
    BAHNSON, RR
    WILSON, JW
    SZUMOWSKI, J
    ERNSTOFF, MS
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1995, 18 (03): : 211 - 215
  • [10] COMBINATION OF RECOMBINANT INTERFERON ALPHA-2A AND VINBLASTINE IN ADVANCED RENAL-CELL CANCER
    BERGERAT, JP
    HERBRECHT, R
    DUFOUR, P
    JACQMIN, D
    BOLLACK, C
    PREVOT, G
    BAILLY, G
    DEGARIS, S
    JURASCHEK, F
    OBERLING, F
    CANCER, 1988, 62 (11) : 2320 - 2324